Fusion Pharmaceuticals Inc.
FUSNNASDAQHealthcare
$21.55
+$0.03(+0.14%)
Market Cap$1.8B
P/E Ratio—
52W High$21.6
52W Low$2.31
Fusion Pharmaceuticals Inc. (FUSN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FUSN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2024Report Date: May 7, 2024EPS Actual
-$0.40
Est. -$0.38 · -5.3%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2024
FY ends December
Report Date
May 7, 2024
After Market Close
▼ Miss EPS
FUSN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q2 FY2024 | May 7, 2024 | -$0.38 | -$0.40 | -5.3% | — | $0.00B | — |
| ▼ Q1 FY2024 | Mar 20, 2024 | -$0.34 | -$0.39 | -14.7% | $0.03B | $0.00B | +8103.9% |
| ▲ Q4 FY2023 | Nov 7, 2023 | -$0.40 | -$0.25 | +37.5% | $0.00B | $0.00B | +772.2% |
| ▲ Q3 FY2023 | Aug 8, 2023 | -$0.39 | -$0.38 | +2.6% | $0.00B | $0.00B | -57.5% |
| ▼ Q2 FY2023 | May 11, 2023 | -$0.29 | -$0.45 | -55.2% | $0.00B | $0.01B | -99.7% |
| ▲ Q1 FY2023 | Mar 16, 2023 | -$0.57 | -$0.55 | +3.5% | $0.00B | $0.00B | +600.0% |
| ▼ Q4 FY2022 | Nov 8, 2022 | -$0.52 | -$0.55 | -5.8% | $0.00B | $0.00B | +66.0% |
| ▲ Q3 FY2022 | Aug 9, 2022 | -$0.53 | -$0.44 | +17.0% | $0.00B | $0.00B | +314.6% |
Q2 FY2024
May 7, 2024Miss
EPS Actual
-$0.40
EPS Est.
-$0.38
EPS Surpr.
-5.3%
Revenue
—
Q1 FY2024
Mar 20, 2024Miss
EPS Actual
-$0.39
EPS Est.
-$0.34
EPS Surpr.
-14.7%
Revenue
$0.03B
Q4 FY2023
Nov 7, 2023Beat
EPS Actual
-$0.25
EPS Est.
-$0.40
EPS Surpr.
+37.5%
Revenue
$0.00B
Q3 FY2023
Aug 8, 2023Beat
EPS Actual
-$0.38
EPS Est.
-$0.39
EPS Surpr.
+2.6%
Revenue
$0.00B
Q2 FY2023
May 11, 2023Miss
EPS Actual
-$0.45
EPS Est.
-$0.29
EPS Surpr.
-55.2%
Revenue
$0.00B
Q1 FY2023
Mar 16, 2023Beat
EPS Actual
-$0.55
EPS Est.
-$0.57
EPS Surpr.
+3.5%
Revenue
$0.00B
Q4 FY2022
Nov 8, 2022Miss
EPS Actual
-$0.55
EPS Est.
-$0.52
EPS Surpr.
-5.8%
Revenue
$0.00B
Q3 FY2022
Aug 9, 2022Beat
EPS Actual
-$0.44
EPS Est.
-$0.53
EPS Surpr.
+17.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.57 | $-0.57 | $-0.57 | 1 |
| Q3 FY2027 | $-0.55 | $-0.55 | $-0.55 | 1 |
| Q2 FY2027 | $-0.49 | $-0.49 | $-0.49 | 1 |
| Q1 FY2027 | $-0.43 | $-0.43 | $-0.43 | 1 |
| Q4 FY2026 | $-0.43 | $-0.43 | $-0.43 | 1 |
| Q3 FY2026 | $-0.42 | $-0.42 | $-0.42 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2024 | May 7, 2024 | -5.3% | $21.42 | $21.40 | -0.09% |
| ▼ Q1 FY2024 | Mar 20, 2024 | -14.7% | $21.18 | $21.09 | -0.42% |
| ▲ Q4 FY2023 | Nov 7, 2023 | +37.5% | $4.31 | $4.50 | +4.41% |
| ▲ Q3 FY2023 | Aug 8, 2023 | +2.6% | $3.02 | $3.02 | +0.00% |
| ▼ Q2 FY2023 | May 11, 2023 | -55.2% | $4.47 | $4.52 | +1.12% |
| ▲ Q1 FY2023 | Mar 16, 2023 | +3.5% | $4.20 | $4.13 | -1.67% |
| ▼ Q4 FY2022 | Nov 8, 2022 | -5.8% | $1.98 | $2.15 | +8.59% |
| ▲ Q3 FY2022 | Aug 9, 2022 | +17.0% | $2.19 | $2.04 | -6.85% |
Q2 FY2024-0.09%
Report Date
May 7, 2024
EPS Beat/Miss
-5.3%
Price Before
$21.42
Price After
$21.40
Q1 FY2024-0.42%
Report Date
Mar 20, 2024
EPS Beat/Miss
-14.7%
Price Before
$21.18
Price After
$21.09
Q4 FY2023+4.41%
Report Date
Nov 7, 2023
EPS Beat/Miss
+37.5%
Price Before
$4.31
Price After
$4.50
Q3 FY2023+0.00%
Report Date
Aug 8, 2023
EPS Beat/Miss
+2.6%
Price Before
$3.02
Price After
$3.02
Q2 FY2023+1.12%
Report Date
May 11, 2023
EPS Beat/Miss
-55.2%
Price Before
$4.47
Price After
$4.52
Q1 FY2023-1.67%
Report Date
Mar 16, 2023
EPS Beat/Miss
+3.5%
Price Before
$4.20
Price After
$4.13
Q4 FY2022+8.59%
Report Date
Nov 8, 2022
EPS Beat/Miss
-5.8%
Price Before
$1.98
Price After
$2.15
Q3 FY2022-6.85%
Report Date
Aug 9, 2022
EPS Beat/Miss
+17.0%
Price Before
$2.19
Price After
$2.04
Avg Beat Reaction-1.03%
Avg Miss Reaction+2.30%
Beat Rate4 / 8 quarters
Largest Move+8.59% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FUSN ends December
Fusion Pharmaceuticals Inc. (FUSN) most recently reported earnings on May 7, 2024 for Q2 FY2024, posting EPS of $-0.40 — missing the analyst consensus of $-0.38 by -5.3%. The next FUSN earnings date is expected around September 1, 2026.
Each quarter, investors track FUSN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FUSN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FUSN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FUSN earnings · 5 questionsFusion Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. FUSN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FUSN historically reports after market close (AMC).
FUSN earnings datewhen is FUSN earningsFUSN next earnings datewhen does FUSN report earningsFUSN earnings calendar
▸ Source: FMP · Fusion Pharmaceuticals Inc. SEC filings · US GAAP · Fusion Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026